Identifies vulnerabilities in RAD51D-deficient tumors, suggesting targeted chemotherapy strategies.
to identify targetable vulnerabilities in RAD51D-deficient tumors. These TNBC cells were significantly more sensitive to cisplatin than wild-type TNBC cells, consistent with our clinical data. In conclusion, RAD51D-deficient tumors were shown to have a phenotype similar to that of BRCA1-deficient tumors, and further investigation of responses to DNA-damaging agents, particularly platinum-based chemotherapy, is warranted.
No takes yet. Share an insight, caveat, or question.
Jo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: